March 10, 2014
Takeda Pharmaceutical said on March 7 that it has submitted a new drug application (NDA) for its type-2 diabetes treatment trelagliptin succinate (development code: SYR-472). It will be the first once-weekly dipeptidyl peptidase 4 (DPP-4) inhibitor in Japan if approved...read more